Artelo Biosciences Inc.

Artelo Biosciences, Inc. (www.artelobio.com) is a clinical stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (the ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. Its programs represent a range of approaches in utilizing the ECS to develop pharmaceuticals for patients with unmet healthcare needs. Its product pipeline includes ART27.13, ART12.11 and ART26.12. ART27.13 is a clinic-ready, potent, peripherally restricted dual synthetic agonist developed for the treatment of cancer-related anorexia and weight loss. ART26.12 is a small molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), being studied both as a cancer therapeutic and in anxiety-related disorders, including post-traumatic stress disorder (PTSD). ART12.11 is a solid-state composition of cannabidiol (CBD cocrystal) for PTSD and inflammatory bowel diseases.

• Artelo Biosciences Inc.